Topic Review
Pathophysiology of Extra-Intestinal Manifestations in Inflammatory Bowel Diseases
Inflammatory bowel diseases (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD), are complex multifactorial chronic inflammatory disorders affecting nearly 7 million patients worldwide, with an increasing prevalence in Northern Europe and emerging countries. IBD can be associated with a wide spectrum of extra-intestinal manifestations (EIMs) with a significant impact on patients’ quality of life. The pathophysiology of EIMs in IBD is intricate and uncertain. The European Crohn’s and Colitis Organization (ECCO) proposed an operational definition of EIMs’ pathology in IBD patients.
  • 117
  • 16 Jan 2024
Topic Review
Morphological Variations of the Liver
Radiologists and oncogynecologists should be familiar with different liver shape variations to avoid diagnostic errors and unwanted intraoperative surgical complications. Surgeons should be aware of variations in liver shape as in such cases, the vasculature or gallbladder may have a variant anatomical location.
  • 387
  • 16 Jan 2024
Topic Review
Diagnosis of Mirizzi Syndrome
Mirizzi syndrome is a complication of gallstone disease caused by an impacted gallstone in the infundibulum of the gallbladder or within the cystic duct, causing chronic inflammation and extrinsic compression of the common hepatic duct or common bile duct. Eventually, mucosal ulceration occurs and progresses to cholecystobiliary fistulation. Numerous systems exist to classify Mirizzi syndrome, with the Csendes classification widely adopted. It describes five types of Mirizzi syndrome according to the presence of a cholecystobiliary fistula and its corresponding severity, and whether a cholecystoenteric fistula is present. 
  • 221
  • 15 Jan 2024
Topic Review
B-Blockers in Liver Cirrhosis
In cirrhotic patients, non-selective b-blockers (NSBBs) constitute the reference treatment of choice as monotherapy or combined with band ligation for the prevention of first variceal bleeding and rebleeding, respectively. Furthermore, the last Baveno VII guidelines recommended carvedilol, a b-blocker with additional anti-a1 receptor activity, in all compensated cirrhotics with clinically significant portal hypertension, to prevent liver decompensation. Interestingly enough, NSBBs have been reported to have a potentially positive impact on the short-term mortality of patients with acute-on-chronic liver failure. 
  • 146
  • 15 Jan 2024
Topic Review
MRI-Based Assessment of Rectal Cancer Post-Neoadjuvant Therapy
Rectal cancer presents significant diagnostic and therapeutic challenges, with neoadjuvant therapy playing a pivotal role in improving resectability and patient outcomes. Magnetic resonance imaging (MRI) serves as a critical tool in assessing treatment response.
  • 253
  • 12 Jan 2024
Topic Review
The Role of IL-23 Inhibitors in Crohn’s Disease
Promoting a Th17 pathogenic response, the interleukin (IL)-23 pathway is crucial in the pathophysiology of inflammatory bowel disease (IBD). With a favorable safety profile, ustekinumab, a monoclonal antibody targeting the shared p40 component of IL-12/23, is currently approved for the treatment of IBD in patients with disease refractory to corticosteroids and biologic drugs. Risankizumab, mirikizumab, and guselkumab are specific IL-23p19 antagonists tested for the treatment of Crohn’s disease (CD). However, only risankizumab currently has been approved for its treatment. Trials with guselkumab and mirikizumab are currently ongoing, with promising preliminary efficacy and safety results.
  • 169
  • 11 Jan 2024
Topic Review
Assessment of Eosinophilic Esophagitis
Eosinophilic esophagitis (EoE) is an immune-mediated disease that manifests with dysphagia and is characterized by the predominantly eosinophilic infiltration of the esophageal mucosa. Several instruments have been developed to assess the symptoms of EoE.
  • 177
  • 11 Jan 2024
Topic Review
Diagnosis of Cytomegalovirus Infection
Cytomegalovirus (CMV) infection is still a matter of concern in Inflammatory Bowel Diseases (IBD) patients, especially regarding the disease’s relapse management. Why IBD patients, particularly those affected by ulcerative colitis, are more susceptible to CMV reactivation is not totally explained, although a weakened immune system could be the reason. 
  • 266
  • 10 Jan 2024
Topic Review
Drug-Induced Acute Pancreatitis in Adults
Acute pancreatitis (AP) is an acute inflammation of the pancreas caused by the activation of digestive enzymes in the pancreatic tissue. The main causes of AP are cholelithiasis and alcohol abuse; less commonly, it can be caused by drugs, with a prevalence of up to 5%. Causal associations between drugs and pancreatitis are largely based on case reports or case series with limited evidence.
  • 427
  • 09 Jan 2024
Topic Review
Liver Tissue Engineering
The liver is the largest gland in the human body, mediating essential functions in homeostasis, metabolism, serum protein production, storage of glycogen, drug detoxification, immune system, and production and secretion of bile acids. The ultimate goal of liver tissue engineering (LTE)  is to restore partial or total function of the liver during liver failure. A fully functional liver is the ultimate aim of LTE, and functional liver tissue can be used for drug testing. Moreover, LTE has the potential to develop an extracorporeal liver support (ECLS) system performing the essential functions of the liver to reduce mortality or to bridge a patient to a liver transplant. With recent advances in the field of regenerative medicine, tissue engineering holds high potential to progress as an alternative or supplement to LT. A major advance in the LTE area was published by Chhabra and colleagues, reporting the development of a vascularized liver model to understand liver regeneration.
  • 400
  • 05 Jan 2024
  • Page
  • of
  • 66
ScholarVision Creations